K. Maheshkumar, Vijayakumar. Venugopal, S. Geethanjali, S. Poonguzhali, S. Silambanan, R. Padmavathi, Sankaralingam Thirupathy Venkateswaran
{"title":"新型冠状病毒(COVID-19)治疗中的补充和替代疗法(CAM):系统评价和荟萃分析方案","authors":"K. Maheshkumar, Vijayakumar. Venugopal, S. Geethanjali, S. Poonguzhali, S. Silambanan, R. Padmavathi, Sankaralingam Thirupathy Venkateswaran","doi":"10.1515/openhe-2022-0009","DOIUrl":null,"url":null,"abstract":"Abstract Background: In December 2019, a new corona-virus (COVID-19) infection broke out in the Chinese province of Wuhan. With the rampant spread of virus around the world, COVID-19 was declared as a global pandemic in the following year. Many complementary and alternate therapies (CAM) were used experimentally alongside conventional treatments for effective management of COVID-19. Aim: This paper presents a protocol for the systematic review and meta-analysis of the studies with various CAM therapies for the management of COVID-19 pneumonia. Methods: Electronic databases such as PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) could be used for searching the relevant trials and studies with keywords related to COVID-19 and CAM therapies. Two independent reviewers would screen a list of all the trials and extract the relevant variables. Additionally, we would also evaluate the risk of bias of the selected studies. Review Manager software (RevMan; version 5.3.5) and R statistical software (version 3.6.1) would be used for the data analysis. Results: Risk ratio (RR) would be estimated for dichotomous outcomes, and the mean differences (MD) would be measured for continuous outcomes. Heterogeneity with the help of I2 statistic would be used for the assessment of inconsistency across studies with the level of significance at P< 0.10. We would also assess publication bias using funnel plots and Egger’s test for the selected studies. Conclusion: The protocol for systematic review and meta-analysis would investigate the beneficial and possible adverse effects of various CAM therapies in the prevention and management of COVID-19 associated pneumonia.","PeriodicalId":74349,"journal":{"name":"Open health data","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Complementary and alternate therapies (CAM) in the management of novel Corona virus (COVID-19): protocol for systematic review and meta-analysis\",\"authors\":\"K. Maheshkumar, Vijayakumar. Venugopal, S. Geethanjali, S. Poonguzhali, S. Silambanan, R. Padmavathi, Sankaralingam Thirupathy Venkateswaran\",\"doi\":\"10.1515/openhe-2022-0009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Background: In December 2019, a new corona-virus (COVID-19) infection broke out in the Chinese province of Wuhan. With the rampant spread of virus around the world, COVID-19 was declared as a global pandemic in the following year. Many complementary and alternate therapies (CAM) were used experimentally alongside conventional treatments for effective management of COVID-19. Aim: This paper presents a protocol for the systematic review and meta-analysis of the studies with various CAM therapies for the management of COVID-19 pneumonia. Methods: Electronic databases such as PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) could be used for searching the relevant trials and studies with keywords related to COVID-19 and CAM therapies. Two independent reviewers would screen a list of all the trials and extract the relevant variables. Additionally, we would also evaluate the risk of bias of the selected studies. Review Manager software (RevMan; version 5.3.5) and R statistical software (version 3.6.1) would be used for the data analysis. Results: Risk ratio (RR) would be estimated for dichotomous outcomes, and the mean differences (MD) would be measured for continuous outcomes. Heterogeneity with the help of I2 statistic would be used for the assessment of inconsistency across studies with the level of significance at P< 0.10. We would also assess publication bias using funnel plots and Egger’s test for the selected studies. Conclusion: The protocol for systematic review and meta-analysis would investigate the beneficial and possible adverse effects of various CAM therapies in the prevention and management of COVID-19 associated pneumonia.\",\"PeriodicalId\":74349,\"journal\":{\"name\":\"Open health data\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open health data\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/openhe-2022-0009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open health data","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/openhe-2022-0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:2019年12月,中国武汉市发生新型冠状病毒(COVID-19)感染。随着新冠疫情在世界范围内的蔓延,第二年被宣布为全球大流行。许多补充和替代疗法(CAM)与常规治疗一起实验性地用于有效管理COVID-19。目的:本文提出了一种系统评价和荟萃分析各种CAM治疗COVID-19肺炎的研究方案。方法:通过PubMed、Embase、Scopus、Cochrane Central Register of Controlled Trials (Central)等电子数据库检索与COVID-19和CAM治疗相关的相关试验和研究。两名独立的审稿人将筛选所有试验的列表并提取相关变量。此外,我们还将评估所选研究的偏倚风险。Review Manager软件(RevMan;5.3.5版本)和R统计软件(3.6.1版本)进行数据分析。结果:二分结局的风险比(RR)将被估计,连续结局的平均差异(MD)将被测量。使用I2统计量的异质性来评估研究间的不一致性,显著性水平为P< 0.10。我们还会对选定的研究使用漏斗图和Egger检验来评估发表偏倚。结论:系统评价和荟萃分析方案将探讨各种CAM疗法在预防和管理COVID-19相关性肺炎中的有益和可能的不良影响。
Complementary and alternate therapies (CAM) in the management of novel Corona virus (COVID-19): protocol for systematic review and meta-analysis
Abstract Background: In December 2019, a new corona-virus (COVID-19) infection broke out in the Chinese province of Wuhan. With the rampant spread of virus around the world, COVID-19 was declared as a global pandemic in the following year. Many complementary and alternate therapies (CAM) were used experimentally alongside conventional treatments for effective management of COVID-19. Aim: This paper presents a protocol for the systematic review and meta-analysis of the studies with various CAM therapies for the management of COVID-19 pneumonia. Methods: Electronic databases such as PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) could be used for searching the relevant trials and studies with keywords related to COVID-19 and CAM therapies. Two independent reviewers would screen a list of all the trials and extract the relevant variables. Additionally, we would also evaluate the risk of bias of the selected studies. Review Manager software (RevMan; version 5.3.5) and R statistical software (version 3.6.1) would be used for the data analysis. Results: Risk ratio (RR) would be estimated for dichotomous outcomes, and the mean differences (MD) would be measured for continuous outcomes. Heterogeneity with the help of I2 statistic would be used for the assessment of inconsistency across studies with the level of significance at P< 0.10. We would also assess publication bias using funnel plots and Egger’s test for the selected studies. Conclusion: The protocol for systematic review and meta-analysis would investigate the beneficial and possible adverse effects of various CAM therapies in the prevention and management of COVID-19 associated pneumonia.